Opus Genetics (IRD) vs. The Competition Head-To-Head Survey

Opus Genetics (NASDAQ:IRD) is one of 1,064 publicly-traded companies in the “Pharmaceutical preparations” industry, but how does it compare to its peers? We will compare Opus Genetics to similar businesses based on the strength of its dividends, institutional ownership, valuation, analyst recommendations, profitability, risk and earnings.

Profitability

This table compares Opus Genetics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Opus Genetics	-324.45%	-63.65%	-56.94%
Opus Genetics Competitors	-3,419.33%	-220.72%	-32.92%

Analyst Ratings

This is a summary of recent recommendations and price targets for Opus Genetics and its peers, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Opus Genetics	0	0	1	0	3.00
Opus Genetics Competitors	8016	21608	49347	1285	2.55

Opus Genetics currently has a consensus price target of $8.00, suggesting a potential upside of 561.16%. As a group, “Pharmaceutical preparations” companies have a potential upside of 182.51%. Given Opus Genetics’ stronger consensus rating and higher probable upside, equities analysts plainly believe Opus Genetics is more favorable than its peers.

Institutional & Insider Ownership

15.0% of Opus Genetics shares are held by institutional investors. Comparatively, 44.2% of shares of all “Pharmaceutical preparations” companies are held by institutional investors. 6.6% of Opus Genetics shares are held by company insiders. Comparatively, 13.6% of shares of all “Pharmaceutical preparations” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Valuation and Earnings

This table compares Opus Genetics and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Opus Genetics	$19.05 million	-$9.99 million	-1.11
Opus Genetics Competitors	$1.78 billion	$126.35 million	-5.89

Opus Genetics’ peers have higher revenue and earnings than Opus Genetics. Opus Genetics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Risk and Volatility

Opus Genetics has a beta of 0.16, suggesting that its stock price is 84% less volatile than the S&P 500. Comparatively, Opus Genetics’ peers have a beta of 3.68, suggesting that their average stock price is 268% more volatile than the S&P 500.

Summary

Opus Genetics peers beat Opus Genetics on 7 of the 13 factors compared.

Opus Genetics Company Profile

Opus Genetics Inc. is a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of unmet needs of patients with refractive and retinal eye disorders. Opus Genetics Inc., formerly known as Ocuphire Pharma Inc., is based in Farmington Hills, Michigan.